De-Escalate
Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial
Description: A pragmatic trial that aims to revisit intermittent androgen deprivation therapy (ADT) in patients with metastatic hormone-naïve prostate cancer.
Study Phase: Phase 3
Principal Investigator: Dr Raheel Khan
Further information